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ABSTRACT  
Genetically engineered neural stem cell (NSC) transplant populations offer key benefits in 
regenerative neurology, for release of therapeutic biomolecules in ex vivo gene therapy. NSCs 
are ‘hard-to-transfect’ but amenable to ‘magnetofection’. Despite the high clinical potential of 
this approach, the low and transient transfection associated with the large size of therapeutic 
DNA constructs is a critical barrier to translation. We demonstrate for the first time that DNA 
minicircles (small DNA vectors encoding essential gene expression components but devoid of 
a bacterial backbone, thereby reducing construct size versus conventional plasmids) deployed 
with magnetofection achieve the highest, safe non-viral DNA transfection levels (up to 54%) 
reported so far for primary NSCs. Minicircle-functionalized magnetic nanoparticle (MNP)-
mediated gene delivery also resulted in sustained gene expression for up to four weeks. All 
daughter cell types of engineered NSCs (neurons, astrocytes and oligodendrocytes) were 
transfected (in contrast to conventional plasmids which usually yield transfected astrocytes 
only), offering advantages for targeted cell engineering. In addition to enhancing MNP 
functionality as gene delivery vectors, minicircle technology provides key benefits from 
safety/scale up perspectives. Therefore, we consider the proof-of-concept of fusion of 
technologies used here offers high potential as a clinically translatable genetic modification 
strategy for cell therapy.  
Keywords:  Minicircles, magnetic nanoparticles, genetic engineering, ex vivo gene therapy, 
neural stem cells; regenerative neurology 
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1. Introduction 
Neural stem cell (NSC) mediated gene therapy holds considerable promise for the treatment 
of diseases, injuries and malignancies of the central nervous system (CNS). NSCs can 
function as a cell source for ‘restorative cell therapeutics’ in sites of neuropathology (given 
their capacity for self-renewal and multipotentiality)
 
[1,2]. They create an environment 
permissive for repair by releasing pro-regenerative and immunosuppressive proteins, and 
these cells have rapidly progressed to clinical trials for several neurological disorders [3–7]. 
NSCs have key properties making them particularly attractive as vehicles for delivery of 
therapeutic molecules to neurological injury sites, such as the ability to migrate long distances 
in nervous tissue. Specifically, they show migration towards pathology sites such as 
tumours/neurodegeneration (termed ‘pathotropism’) [8,9]. Intravenously delivered NSCs can 
cross the blood-brain barrier surrounding neural tissue into pathology foci - a phenomenon 
modulated by inflammation, astrocytosis and blood vessel formation - minimising adverse 
effects in surrounding normal host tissue [10]. These cells can be propagated for extended 
periods in culture offering flexibility for genetic modification techniques. Additionally, they 
show functional integration into the host microenvironment with little evidence of adverse 
consequences [10]. Therefore, a widely held belief is that these cells could aid in overcoming 
a major challenge of CNS gene therapy, namely, how to safely and effectively target 
therapeutic genes to diseased/injured tissue. This is particularly relevant to complex 
neurological pathologies wherein multiple therapeutic targets must be addressed to achieve 
repair (i.e. ‘combinatorial therapy’) [11].  
Several preclinical models of CNS pathology have demonstrated the utility of genetically 
engineered NSCs for improving functional neurological outcomes [12–16]. Recent data prove 
that transplantation of NSCs engineered to release insulin-like growth factor (IGF-1) reduced 
plaque pathology and enhanced learning, cognitive and memory processes in a mouse model 
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of Alzheimer’s disease (www.neuralstem.com). Additionally, retrovirally-transduced cytosine 
deaminase-expressing NSCs in combination with leucovorin are currently being tested in 
human clinical trials for treatment of recurrent high grade gliomas (www.clinicaltrials.gov, 
Clinical trial ID NCT0117296) having successfully passed a pilot feasibility study. It should 
be noted here that current genetic engineering approaches for NSCs almost exclusively rely on 
viral methods due to the high transduction efficiencies achieved (up to ca 97%) [17]. 
However, viral gene delivery has significant drawbacks restricting clinical use including 
immunogenicity, toxicity and technical challenges for large scale production [18–20]. 
A major non-viral alternative for neural gene transfer that has emerged relatively recently is 
‘magnetofection’ wherein transfection-grade iron oxide magnetic nanoparticles (MNPs) are 
deployed with magnetic fields (static/oscillating) to assist gene delivery. We recently reported 
technically simple, rapid and safe magnetofection protocols for genetic modification of major 
neural transplant types including NSCs, with oscillating magnetic fields always outperforming 
static fields [21–25]. MNPs have emerged strongly as a class of advanced functional materials 
for neuro-regeneration, serving as ‘multifunctional tools’ for cell therapy given additional 
applications for non-invasive cell imaging and magnetic cell targeting, so it is clear that this 
non-viral gene transfer method offers significant benefits for clinical translation [26].
 
Despite 
the critical advantages offered by this technique, we and others have reported that DNA 
plasmid size bears an inverse relationship with transfection efficiency for non-viral methods 
such as liposome- and nanoparticle- mediated transfection [23,27–29]. For example, using 
lipofection, a systematic analysis of luciferase expression levels (using reporter constructs of 
increasing size; 4.8 kb to 10.5 kb) showed reduced transfection with greater plasmid size [29]. 
This finding was consistent across various promoters (SV40 and γ-globin gene promoter) and 
cell lines (Jurkat and 293T) tested [29]. The reasons for this differential effect are largely 
unknown, but the gross structure of plasmid/lipid complexes was ruled out as similar 
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physicochemical properties (lipoplex structure and size) were observed irrespective of 
plasmid size (0.9 kb to 52.5 kb) [29]. Similarly, we reported an inverse relationship between 
transfection efficiency and plasmid size when using reporter plasmids (3.6 kb, transfection 
efficiency, ca. 32.2%) versus therapeutic constructs encoding basic fibroblast growth factor 
(7.4 kb, transfection efficiency: 13.5%) [23].
 
As therapeutic DNA constructs inevitably 
increase DNA size using conventional plasmids, this reduction in transfection efficiency and 
the functionality of nanoparticle vectors, is a critical translational barrier for ex vivo neural 
gene therapy.
 
Offering a potential solution, minicircles (mCs) are emerging as highly promising DNA 
vectors for therapeutic gene delivery. These are small circular vectors devoid of bacterial 
backbone sequences e.g. antibiotic resistance genes, origin of replication and other 
inflammatory sequences, intrinsic to bacterial DNA. These minimal expression cassettes are 
derived from ‘parental’ plasmid (pp) DNA, through site-specific recombination (induced via 
L-arabinose operon system). Their use results in sustained transgene expression due to lower 
activation of nuclear transgene silencing mechanisms, and reduced immunogenic responses 
[30]; the latter resulting in higher safety. The clinical potential of mCs has been exploited for 
non-viral DNA reprogramming to generate human induced pluripotent stem cells [31]. An 
analysis of mC DNA transfection in a murine stem cell line CGR8-NS using microporation 
reported up to 60% transfection with high cell survival (~90%) [32]. However, such cell lines 
have high survival rates given their resistance to nanotoxicity, and behave in a relatively 
uniform clonal manner. It is therefore critical to evaluate the efficacy of  DNA mC technology 
in primary NSC, as these heterogeneous but hard-to-transfect cell populations are more akin 
to NSCs in vivo, and consequently of higher biomedical relevance. Furthermore, it should also 
be noted that mC use in conjunction with magnetofection has never been tested in any cell 
type of primary origin. Accordingly, our goal here is to provide the first ‘proof-of-concept’ 
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that mC DNA vector functionalized MNPs can be used with oscillating magnetofection 
technology for efficacious genetic engineering of primary NSCs.  
2. Materials and Methods  
 
2.1. Reagents / equipment 
Cell culture reagents were from Life technologies (Paisley, Scotland, UK) and Sigma (Polle, 
Dorset, UK). Human recombinant basic fibroblast growth factor (bFGF) was from Sigma 
(Poole, Dorset, UK) and human recombinant epidermal growth factor (EGF) from R&D 
Systems Europe Ltd. (Abingdon, UK). Thermo Scientific Nunc culture dishes (non-treated 
surface) and tissue culture-grade plastics were from Fisher Scientific UK (Loughborough, 
UK). NeuroMag magnetic particles were from OZ Biosciences, Marseille, France. The 
magnefect-nano 24-magnet array system was purchased from nanoTherics Ltd. (Stoke-on-
Trent, UK) and comprises horizontal arrays of NdFeB magnets (grade N42) onto which 24-
well cell culture plates can be placed. Reagents used for the mC DNA vector technology were 
from System Biosciences (SBI; Mountain View, CA, USA). All electrophoresis reagents were 
from Life Technologies (Paisley, Scotland,UK). Primary antibodies were directed to: the NSC 
markers, nestin (clone 25, BD Biosciences, Oxford, UK) and SOX2 (Millipore, Watford, 
UK); neuronal marker, class III β-tubulin (clone TUJ1, Covance, Princeton, NJ, USA); the 
oligodendrocyte marker, myelin basic protein (MBP; clone 12, AbD Serotec, Kidlington, 
UK); the astrocytic marker glial fibrillary acidic protein (GFAP; DakoCytomation, Ely, UK), 
proliferation marker Ki-67 (Abcam, Cambridge, UK) and GFP (ThermoFisher Scientific, 
Rockford, IL,USA). Cy-3 and FITC conjugated secondary antibodies were from Jackson 
Immunoresearch Laboratories Ltd (Westgrove, PA, USA). Vectashield mounting medium 
with 4’,6-diamidino-2-phenylindole (DAPI, nuclear marker) was from Vector Laboratories 
(Peterborough, UK). 
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2.2. NSC culture 
The care and use of all animals used in the production of cell cultures were in accordance with 
the Animals Scientific Procedures Act of 1986 (UK).   
NSCs were maintained and expanded under growth factor stimulation as free floating cellular 
aggregates according to the well characterised ‘neurosphere’ culture method. Briefly, the 
subventricular zone of neonatal CD1 mice were dissected, dissociated and NSCs were 
cultured in neurosphere medium (NS-M) comprising a 3:1 mix of DMEM:F12 containing 2% 
B-27 supplement, 50 U/ml penicillin, 50 mg/ml streptomycin, 4 ng/ml heparin, 20 ng/ml 
bFGF and 20 ng/ml EGF. Neurospheres were fed every 2-3 days and passaged every 6-7 days 
using an Accutase-DNaseI mix (up to passage 2).  
 
2.3. Monolayer cultures 
 To prepare two-dimensional adherent NSC monolayers, neurospheres (passages 0 – 2) were 
dissociated enzymatically with accutase-DNase I, triturated several times before resuspension 
at 1.5 x 10
5
 cells/ml monolayer culture medium (ML-M; comprising of a 1:1 mix of 
DMEM:F12 containing 1% N2 supplement, 50 U/ml penicillin, 50 μg/ml streptomycin, 4 
ng/ml heparin, 20 ng/ml FGF2 and 20 ng/ml EGF). The cells were seeded on 
polyornithine/laminin-coated, nitric acid-washed glass coverslips in 24-well plates (0.6 ml 
suspension/well) and cultured at 37 ºC in 95% air:5% CO2.   
2.4. NSC differentiation 
 In order to induce NSC differentiation into the three daughter cell types (neurons, astrocytes, 
oligodendrocytes), ML-M was replaced with differentiation medium (DF-M) consisting of 
NS-M (without growth factors) and supplemented with 1% fetal bovine serum. Medium was 
replaced every 2-3 days. 
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2.5. Minicircle production 
 A mC system was employed to address the influence of plasmid size and copy number on the 
efficacy of MNP-mediated gene transfection. This system comprises a parental plasmid 
pMC.CMV-GFP-SV40PolyA (herein termed pp-GFP; size 5562 bp) from which recombinant 
mCs (mC-GFP; size 1552 bp) lacking extraneous bacterial backbone sequences were prepared 
using a specifically engineered E. coli strain (ZYCY10P3S2T) which was induced to express 
ϕC31 integrase and SceI endonuclease upon addition of arabinose (0.01% final 
concentration), as per the manufacturer’s instructions and previously described protocols [33]. 
The integrase splits the full size pp-GFP to (i) the backbone sequence containing SceI sites for 
targeted endonuclease degradation and (ii) mC DNA containing only the expression cassette 
which was purified. Thus it is possible to obtain DNA preparations which differ markedly in 
size but contain identical elements for mammalian gene expression, including the reporter 
gene per se. 
Following mC purification using a Qiagen Endofree Maxiprep Kit, restriction enzyme digests 
of both pp-GFP and mC-GFP were run on an agarose gel in order to demonstrate the absence 
of pp-GFP contamination in mC-GFP plasmid stocks. In the presence of pp-GFP 
contamination, mC-GFP was digested with mC-safe DNase according to the manufacturer’s 
instructions.   
2.6. MNP characterization, magnetofection and multifection 
The Neuromag particles used here for transfection have been extensively characterized 
previously [34,35]. The formulation of fluorescent Neuromag particles is proprietary and 
patented by the company Oz Biosciences. The particle size range reported by the company is 
140–200 nm, average 160 nm with homogeneity in particle size (polydispersity index 0.027), 
and the particles carrying a positive charge (zeta potential +40.3 mV) in distilled water. 
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Dynamic light scattering (DLS) was used to determine the average hydrodynamic diameter 
and ζ-potential of the MNPs and MNP-DNA complexes which were suspended in 
DMEM:F12 base medium within which the transfection complexes were formed prior to 
addition to cells. This was carried out using a Zetasizer Nano ZS (Malvern Instruments 
Ltd,UK).  
In order to achieve the highest possible transfection level, a range of plasmid copy numbers 
were assessed. At 24 h post-plating, medium was replaced with fresh ML-M (0.225 ml) 
before addition of transfection complexes. To prepare the particle-DNA complexes, varying 
amounts of DNA vectors (see below) were diluted with 75 µl DMEM:F12 (1:1) base medium, 
added to 0.62 µl Neuromag and mixed and incubated for 20 min at room temperature (RT). 
DNA input was varied to obtain six different copy numbers of each DNA vector (pp-GFP and 
mC-GFP) per well: 1.2 x 10
10
, 2.3 x 10
10
, 4.2 x 10
10
, 1.5 x 10
11
, 3 x 10
11
 and 6 x 10
11
. The mix 
was added drop-wise to cells whilst gently swirling the plate. Plates were returned to the 
incubator, and exposed to a magnetic field using the magnefect-nano oscillating magnetic 
array system, with a 24-magnet array (NdFeB, grade N42; field strength of 421 ± 20 mT) with 
an oscillating frequency of 4Hz (amplitude = 0.2 mm). The array moves laterally with 
oscillation frequency and amplitude controlled via a computerised motor. For single 
transfection, complexes were left for 48 h until fixation. For double transfection, the exact 
same protocol was followed, with a 24 h time window between the first and second 
transfection. The following procedures were carried out 48 h after the first transfection: (i) 
Cells were fixed in PFA for immunocytochemistry (to assess for transfection efficiency, 
proliferative capacity and stemness); (ii) The media was switched to DF-M and the cells were 
allowed to differentiate for three days, one week or four weeks (to assess for long term GFP 
expression, differentiation capacity and quantify transfected differentiated progeny) before 
PFA fixation. For long-term cultures, media was replaced every two days. (iii) Live cells were 
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stained for 15 minutes with propidium iodide (PI, prepared in fresh medium at a final 
concentration 5µM) prior to fixation (for cell death quantification). (iv) DAPI-stained fixed 
samples were used to corroborate cell pyknosis (counts of small, fragmented nuclei) and total 
cell number.  
2.7. Assessment of DNA vector binding to MNPs  
The nanoparticle/DNA reaction was performed as above, in a smaller volume of 20µl base 
medium. Samples were centrifuged at 14,000 rpm for 5 minutes to remove particle and 
particle/DNA complexes. The absorbance of the supernatant which contained the 
free/unbound DNA was measured at 260nm against a DMEM blank. Absorbance was also 
measured for the particle-free (with equivalent DNA copy number) sample in order to obtain 
accurate input DNA measurements. The amount of DNA bound to MNPs was calculated as:  
% MP - bound DNA = 100 – [(total ‘free’ DNA in supernatant/ total input DNA) x 100].  
2.8. Immunocytochemistry 
NSC monolayers and differentiated NSCs were fixed in 4% paraformaldehyde (PFA) for 15 
min at RT, followed by three washes in PBS. Non-specific binding was blocked using 5% 
normal donkey serum in PBS-0.3% Triton-X-100 for 30 min at RT, followed by overnight 
primary antibody incubation at 4°C. The following antibodies in blocking solution were 
added at the indicated dilutions: Sox2, 1:1000 and Nestin, 1:200; GFAP, 1:500; Tuj1, 1:1000; 
MBP, 1:200; Ki-67, 1:500 and GFP, 1:1000. The use of the GFP antibody enhanced the 
detection of GFP in these cells. This is because copGFP (the reporter protein expressed from 
the parental plasmid and mC vectors), is a natural GFP found in the copepod Pontellina 
plumata whose fluorescence intensity is less than the widely used mutated versions such as 
TurboGFP and maxGFP. The advantages of using this form of GFP however, is that it is non-
toxic and non-aggregating which is important for assessment of GFP expression in long term 
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cultures, which is carried out in this study. Therefore all samples were co-stained with this 
antibody. The following day, after several washes in PBS, samples were blocked as above and 
incubated with either FITC-or Cy3-labelled secondary antibody (1:200) in blocking solution 
at RT for 2 h. Samples were washed thrice in PBS before mounting with Vectashield 
mounting medium containing DAPI.  
2.9. Microscopic analysis 
An AxioScope A1 microscope equipped with an Axio Cam ICc1 digital camera and 
AxioVision software (version 4.7.1, Carl Ziess MicroImaging GmbH, Goettingen, Germany) 
was used for fluorescence imaging and obtaining photomicrographs. For all quantitative 
analyses, a minimum of 2000 cells were counted across 3-4 random fields using Image J 
software. Cells were identified by fluorescence microscopy using cell-specific immunological 
markers co-localised with their nuclei using DAPI. Percentage transfection efficiency was 
determined by: the number of cells expressing GFP/ total number of DAPI
+
 cells. The 
fluorescence intensity was determined by calculating corrected total cell fluorescence (CTCF) 
using the formula: CTCF = Integrated density–(Area of selected cell x Mean fluorescence of 
background readings) using the ImageJ 1.47 Software (NIH). Quantification measurements 
performed in the same quadrant of randomly selected fields to avoid cell selection bias; a 
minimum of 90 cells were counted for each condition.  
  
2.10. Statistical analyses 
Treatment groups were analysed either by one-way analysis of variance and Bonferroni’s 
multiple comparison test or an independent sample Student’s t-tests, using Prism software 
(version 6.07; Graphpad, USA). Each error bar represents the standard error of the mean of a 
minimum of three separate experiments. The number of experiments (n) refers to the number 
of NSC cultures which are each generated from a different mouse litter. 
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3. Results and Discussion  
 
3.1. High purity derivation of cell cultures and mC DNA vector  
The NSC cultures used in this study were of high purity as judged by staining NSC markers 
Nestin, a cytoskeletal protein (purity: 96.1 ± 2.0%, n = 3) and Sox2, a transcription factor 
(purity: 96.7 ± 0.8%, n = 3). The two DNA vectors employed in this study (for direct 
comparative assessment of plasmid size on transfection efficiency) are shown in Fig. 1. The 
parental plasmid expressing green fluorescent protein (termed pp-GFP, Fig. 1A) is a 
conventional bacterial plasmid containing a kanamycin resistance gene, with GFP expression 
driven by a cytomegalovirus (CMV) promoter. It also contains two recombinase target 
sequences, which through a site-specific recombination event, is used to derive mC DNA 
(mC-GFP, Fig. 1A) which contains only the expression cassette present in pp-GFP. As mC-
GFP is derived from pp-GFP, both vectors express the same variant of GFP. The parental 
plasmid / mC system is ideal for testing plasmid size relationships as differences in vector 
sequences and reporter gene variance can be ruled out as confounding variables. The bacterial 
backbone is excised and degraded in the process (Bb, Fig. 1A). Plasmid digests of both pp-
GFP and mC-GFP with NotI (Fig. 1B) revealed the expected fragment sizes by gel 
electrophoresis, and also demonstrated the absence of parental plasmid contamination in the 
mC preparation. 
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Fig.1. (A) Schematic showing DNA vector maps and their relative sizes (in kb) of parental 
plasmid pp-GFP, the corresponding mC derivative, mC-GFP and the excised bacterial 
backbone (Bb) following mC induction. (B) Agarose gel electrophoresis of NotI restriction 
digests of pp-GFP and mC-GFP run alongside a 1 kb DNA marker displaying the expected 
fragment band sizes of both DNA vectors. 
 
3.2. Minicircle use with magnetofection dramatically enhances NSC gene transfer levels 
Most non-viral studies employ DNA vectors expressing variants of GFP that provide 
enhanced levels of brightness such as TurboGFP and TagGFP [23,36], whereas in this study, 
pp-GFP and mC-GFP express a non-toxic, non-aggregating but less bright ‘copGFP’. The 
advantage of expressing this natural form of the protein enables analyses of GFP expression 
over a long period with less protein crystallization and aggregation resulting in lower toxicity 
in cells. However, to increase detection levels an anti- GFP antibody was used; GFP 
immunostaining significantly enhanced protein detection as depicted in Fig. 2A compared to 
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native GFP expression (inset), with protein expression observed throughout the cell body 
using both plasmids. Hence all samples were analyzed following GFP immunostaining for 
subsequent experiments.  
In order to optimize protocols to achieve high transfection levels, a range of pp-GFP and mC-
GFP copy numbers per well were assessed; the oscillation frequency previously determined to 
be optimal for NSC transfection (4Hz) was used for all experiments [23]. Transfection 
efficiency was overall lower in cells transfected with pp-GFP compared to mC-GFP, with the 
highest transfection efficiency observed when using a mC copy number of 6 x 10
11
. 
Transfected cells for pp-GFP and mC-GFP at this copy number are shown in Fig. 2B and C 
respectively. Standard transfection protocols report MNP:DNA ratios using DNA weight 
which can conceal differences in the actual copy number of DNA vectors present. Therefore, 
transfection results here are presented as a function of both plasmid copy number (Fig. 2D) 
and the corresponding DNA weight (Fig. 2E). At the lowest plasmid copy number (1.2 x10
10
 
per well), there was no difference in the number of transfected cells between pp-GFP and mC-
GFP with mean transfection efficiencies of <10% (Fig. 2D). The highest transfection 
efficiency achieved with pp-GFP was 15.4% at a copy number of 3 x 10
11
 and a further 
increase in copy number resulted in reduced transfection. For mC-GFP, a further increase in 
copy number to 6 x 10
11 
yielded a statistically significant and dramatically higher transfection 
efficiency compared to pp-GFP (transfection efficiency range 42.1 – 45.4% versus 13.4 – 
13.8%). Therefore, for subsequent experiments, this copy number was used for double 
transfection (multifection) in order to yield maximal gene transfer. Double 
transduction/transfection is routinely used for many viral as well as non-viral genetic 
modification approaches such as lipid-mediated gene delivery and electroporation in order to 
enhance transfection efficiency and to prolong gene expression [37–39]. We previously 
showed that multifection of NSCs (cultured as 3-D neurospheres) resulted in higher 
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transfection levels (~27%) compared to single transfection (~13%) with no effect on cell 
physiology and health [22]. NSC monolayers multifected here with mC-GFP showed 
significantly higher transfection (see Fig. 2F versus Fig. 2C) with a range of 50.7 – 54.4% 
versus 15.1 – 20.5% for pp-GFP (Fig. 2G). Transfection levels for mC-GFP multifection were 
also significantly higher than when using single transfection (p < 0.001, student’s t-test, n=3). 
To our knowledge, these are the highest non-viral DNA transfection levels reported to date for 
the hard-to-transfect population of primary NSCs. Our data are in line with a previous 
systematic study in which mC-magnetofection technology applied to HeLa cell lines showed 
an inverse relationship of DNA size on transfection efficiency [40]. 
It could be argued that higher numbers of transfected cells can be achieved by selectively 
enriching for these cells through antibiotic selection or flow cytometry/single-cell sorting. 
However, both approaches are associated with high costs and additional manipulations of 
cells can alter physiology and function [41,42]. Further, loss of non-transfected healthy cells 
(through cell death or discarding associated with these methods) is undesirable given the 
limited tissue availability and ethical concerns associated with human tissue and embryonic 
stem cells and that generation and maintenance of primary NSCs is costly and laborious. 
Therefore the optimal approach currently appears to be transplantation of a mixed population 
of engineered and non-engineered cells.  
Total cell fluorescence intensity measurements revealed significantly higher GFP expression 
in NSCs transfected with mC-GFP compared to pp-GFP (Fig. 2H), suggesting that an 
increased number of expression cassettes are present per transfected cell for mC-GFP 
engineered cells; fluorescence intensity per cell was more than doubled using mC-
multifection versus single transfection (Fig. 2H). A previous study in which cell sorting of 
GFP- and luciferase- expressing mouse melanoma cells (B16F10)  reported  that the ‘high 
expressing sub-population’  demonstrated two-fold higher luciferase expression and three 
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times higher plasmids/nucleus in comparison to their ‘low expressing’ counterparts [38]. To 
further explain this phenomenon, our observations in DNA binding experiments showed that, 
at each copy number assessed, a higher number of mCs copies are bound to MNPs versus 
parental plasmid (Fig. 2I). Our results suggest that as each MNP can only complex a fixed 
maximum mass of DNA and given their small size, mCs have different binding properties 
(enabling efficient binding) compared to larger plasmids (which are approximately 3.5 times 
larger in size than mCs).  Therefore, it is feasible that increased loading of mCs per particle (~ 
3.5 times more mCs than parental plasmids) accounts for the higher gene transfer efficiency 
observed in mC-engineered cells, which was approximately 3.5-fold higher than pp-
engineered NSCs. Additionally, differences in physical binding and subsequent cleavage of 
DNA from the carrier MNP between pp DNA and mC DNA also cannot be ruled out. It 
should be noted that a previous report where equal copy numbers of both DNA vectors were 
microporated into cells also suggested higher mC number within nuclei versus the parental 
counterpart (63.7% vs 18.3%) [32].
 
It has been reasoned that low molecular weight DNA has 
a ‘higher survival rate’, making it more likely to enter the nucleus for two reasons: (i) higher 
mobility, therefore it is less likely to be degraded by host nucleases due to lower time of 
residence in the cytoplasm [43,44] and (ii) improved release of smaller DNA molecules from 
nanoparticles allowing for quicker transportation to the nucleus [27]. Together these data 
indicate that mC use can enhance the level of protein expression per cell, of high relevance to 
release of therapeutic proteins to promote regeneration.  
Furthermore, it is well known that the size and charge of MNP-DNA complexes during 
magnetofection procedures can impact transfection outcomes. However, in our study the DLS 
measurements showed only small differences in hydrodynamic diameter and surface charge 
(Figure 2I) between pp-GFP and mC-GFP functionalised MNPs. These findings suggest that 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
  
17 
 
differences in the physicochemical properties of the particle-plasmid complexes are not likely 
to be the primary explanation for the differences in transfection levels obtained. 
 
 
Fig. 2. Enhanced gene transfer of NSC monolayers with mCs compared to parental 
plasmid. (A) Representative triple-merged image of GFP-stained NSC monolayers transfected 
with mC-GFP showing enhanced GFP detection (equivalent DAPI/GFP double-merged 
image shown in inset). Representative image of GFP immunostained NSC cultures at 48 h 
post transfection with (B) pp-GFP and (C) mC-GFP at the same copy number (6 x 10
11
 copies 
per well); insets show the respective DAPI stained images indicating similar cell densities. 
(D) Relationship between transfection efficiency and plasmid copy number. (E) Relationship 
between transfection efficiency and plasmid weight. (F) Representative image showing NSC 
multifection using mC-GFP at 6 x 10
11
 copies per well, inset showing cell density comparable 
to that used for single transfections shown above. (G) Bar chart showing quantitative analysis 
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of transfection efficiency following multifection with pp-GFP and mC-GFP. (H) Corrected 
total cell fluorescence measurements for single and double transfected NSCs at 6 x 10
11
 
copies per well of pp-GFP and mC-GFP. A.u. denotes arbitory units. *p < 0.05, **p < 0.01, 
***p < 0.001, versus pp-GFP (student’s t-test), n=4 cultures for all graphs. (I) Upper panel 
showing quantitative analysis of DNA bound to equivalent number of MNPs; three identical 
copy numbers of pp-GFP and mC-GFP were tested. Mean ± SEM from three different 
experiments are shown. Lower panel displaying hydrodynamic diameter (Z-average) and 
surface charge (ζ-potential) of naked MNPs and particles functionalized with pp-GFP and 
mC-GFP. DLS denotes dynamic light scattering. 
3.3. High protocol safety with combined use of minicircle vectors and magnetofection 
The effect of multifection on cell health and cell physiology was assessed to evaluate the 
safety of our protocols.  The majority of transfected cells at 48 hours post-transfection, 
showed normal bipolar morphologies with round healthy nuclei and normal adherence 
indicating high viability. Multifected NSCs (both pp-GFP and mC-GFP retained their normal 
morphologies and stem cell marker expression for both Nestin and Sox2 (Fig. 3A and inset). 
Quantitative analyses revealed comparable numbers of Nestin and Sox2 positive cells for pp-
GFP, mC-GFP and non-transfected conditions (Fig. 3B and C respectively). Assessment of 
proliferative capacity, at 48 hours post-transfection, using Ki-67, an endogenous nuclear 
marker for cell division (Fig. 3D) revealed no differences between the three groups (Fig. 3E); 
GFP positive cells showed proliferative ability (inset) with similar proportions of dividing 
cells as non-transfected cells (63.7 ± 3.6% and 66.7 ± 3.1% respectively). Similarly, 
negligible differences were observed in cell viability based on cell number (Fig. 3F). 
Pyknosis/cell death was assessed morphologically by quantifying propidium iodide (PI, a 
fluorescent intercalating DNA stain that is non-permeant to live cells) positive
 
nuclei (Fig. 
3G, arrows and 3H) as well as nuclear shrinkage and fragmentation (Fig. 3G inset and 3I) and 
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showed no differences between conditions. Although, multifection has previously been used 
for NSC neurospheres, demonstrating high viability and cell survival [23], these data are the 
first demonstration of the safety and efficacy of mC transfection in primary NSCs. The high 
safety of the methods highlights the translational potential of the methodology for clinical cell 
therapies.  
 
 
Fig. 3. Safety assessment of multifected NSCs. Representative merged images of NSCs 
multifected with mC-GFP showing stem cell marker expression of (A) Nestin and (A – inset) 
Sox2. Bar charts showing quantification of (B) Nestin
+
 and (C) Sox2
+
 cells. (D) Merged 
image of mC-GFP multifected NSCs with Ki-67, a marker for proliferation, inset showing 
transfected cells also expressing Ki-67 (arrowheads). Bar chart showing no significant 
differences in (E) proliferation and (F) average cell number per field between the transfected 
and non-transfected groups. (G) Merged images of propidium iodide (PI) stained cells 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
  
20 
 
(arrows) and cell pyknosis (inset, arrowheads). (H) Bar charts displaying PI
+
 and (I) 
pyknotic nuclei counts.  
 
3.4. Minicircle use skews profile of transfected progeny of NSCs towards hard-to-
transfect neurons and oligodendrocytes 
Genetically engineered NSCs were allowed to differentiate into their three daughter cell types 
in order to determine whether the protocols can alter the fate or proportion of the daughter cell 
populations. This is an important parameter to consider for clinical translation as NSC 
multipotency (ability to generate the three major cell types of the nervous system) is a key 
element of their therapeutic capacity. Post-differentiation, overall transfection was lower in 
the progeny of NSCs transfected with pp-GFP versus mC-GFP (Fig. 4A, B and H). 
Microscopic assessment revealed normal cellular and nuclear morphologies of the daughter 
populations (Fig. 4C, D, E). The protocols did not alter the relative proportions of each 
daughter cell type generated demonstrating that following multifection NSCs retained their 
potential to differentiate. Astrocytes were the main transfected daughter cells for both pp-GFP 
and mC-GFP, however a higher number of transfected neurons was obtained using mC-GFP. 
It is noteworthy that using mCs, we have obtained transfected daughter oligodendrocytes for 
the first time (Fig. 4H); a phenomenon we have never observed using conventional plasmids. 
Although the numbers of transfected neurons/oligodendrocytes were small, it does appear that 
use of larger plasmids restricts the profile of transfected progeny towards a single cell type. 
This restriction appears to be reduced with mC use, or at least increases chances of obtaining 
in genetically engineered ‘hard-to-transfect’ cells, which would offer a significant advantage 
when using mC DNA vectors compared to their larger plasmid counterpart. The reasons for 
this altered profile are unclear and future work will need to focus on further enhancing the 
numbers of specific transfected cell types. However, this observation has important 
implications for cell replacement therapy as targeted cell engineering of daughter cells 
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especially neurons and oligodendrocytes can significantly impact functional/regenerative 
outcomes. For example, transfected neurons engineered to express BDNF show increased 
axonal sprouting and dendrite number in organotypic rat hippocampal explants [45].
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Fig. 4. Effect of differentiation on transfected NSCs. NSCs multifected with (A) pp-GFP and 
(B) mC-GFP post-differentiation. Representative triple merged images of multifected NSCs 
three days post-differentiation showing (C and D) GFAP
+
/GFP
+ 
Type I and Type II astrocytes 
respectively, (E and inset) MBP
+
/GFP
+
 oligodendrocytes and (F and inset) Tuj1
+
/GFP
+
 
neuron. (G) Bar graph comparing proportions of the daughter cell types of multifected and 
non-transfected NSCs following differentiation. One way analysis of variance with 
Bonferonni’s post-tests, n = 3. (H) Quantitative analysis showing overall transfection profile 
and skewed transfection towards neurons and oligodendrocytes using mC-GFP. 
 a
 p < 0.05,
 b 
p < 0.005 vs pp-GFP (student’s t-test, n = 3).  
 
 
3.5. Minicircle engineering of NSCs results in sustained gene expression 
Microscopic observations revealed no obvious differences in cell morphology and adherence 
between vector-treated cells and untreated controls over time. Cell viability at four weeks, as 
judged by proportions of pyknotic nuclei showed no differences between groups (3.9 ± 0.4% 
for untransfected cells, 4.1±0.4% for pp-GFP and 4.0± 0.3% for mC-GFP). Our data 
demonstrate the long term protocol safety of the multifection approach.  
 
In our study, gene expression was assessed in differentiated NSCs, as differentiation is the 
natural fate of NSCs post-transplantation therefore we consider the analysis to be of greater 
relevance for engineered cell therapy, than studying long term expression in NSCs [43,44]. 
Fluorescence measurements were made in astrocytes as this was the predominant transfected 
population at all time points. mC-GFP engineered cells displayed a higher numbers of 
transfected cells versus pp-GFP, for up to four weeks (Fig. 5A-E). Cell fluorescence intensity 
indicative of protein expression level (Fig. 5F) also showed significantly greater protein 
expression in mC-GFP transfected cells. Our finding that mC-engineered cells contain higher 
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GFP expression cassettes than pp-engineered cells likely explains the higher and sustained 
levels of protein expression seen in the mC engineered NSC population. Additionally it is 
possible that these cells have an intrinsic capacity to maintain exogenous DNA for longer 
periods, or alternatively, generate a greater proportion of stable transfectants.  
 
In our recent study using a conventional pmax-GFP plasmid (3.6 kb), transfection efficiency 
in magnetofected NSCs was assessed up to 2 weeks reporting ‘low’ transfection (≤10% cells) 
[23].
 
 mC transfection with microporation in parent NSCs in a separate study showed 
transfection efficiency of ca. 20% at 10 days post-transfection, but longer time points were 
not studied [32]. It is possible that the prolonged gene expression with mC DNA versus 
conventional plasmids is due to the lack of transcriptional silencing associated with the 
presence of unmethylated CpG islands [30,46]. The removal of these individual sequences 
using conventional molecular biology cloning techniques is laborious and expensive; in 
comparison the mC DNA technology enables a facile, cheaper approach for eliminating 
bacterial sequences, involving fewer and less time consuming procedures. It must be noted 
that the viral promoter  used to drive the transgene expression (CMV) has been demonstrated 
in some studies to be a relatively weak promoter and likely to be silenced in undifferentiated 
mammalian stem cells [47,48]. This highlights the importance of using other effective 
promoters such as elongation factor 1 alpha (EF1a) in order to achieve higher and prolonged 
expression in vivo, an approach that we have employed in Part II of this study, submitted [49]. 
Neurorestoration requires long-term therapeutic intervention [50–52] so from a clinical 
perspective, achieving sustained gene/protein expression can significantly reduce costs and 
time by reducing the need for repeat administration of therapeutic proteins/cells. Notably, a 
sustained yet tapered profile of therapeutic biomolecule expression may be beneficial as it 
mirrors the temporal pattern of molecular expression profiles that are associated with 
regenerative processes in pathology sites [22].
 
Indeed, it has been suggested that 
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overexpression of therapeutic biomolecules for inappropriate periods can have detrimental 
effects on regenerative processes [53].
 
 
 
 
 
Fig. 5. Sustained gene delivery using mCs. Representative image of GFP immunostained 
differentiated NSCs transfected with (A) pp-GFP and (B) mC-GFP (as NSCs) one week post-
transfection and four weeks post transfection (C and D respectively). Bar graphs showing (E) 
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transfection efficiency and (F) extent of cell fluorescence in pp-GFP and mC-GFP at both 
time points (students t-test, n = 3). a.u. denotes arbitory units. 
3.6. MC DNA vector technology offers key benefits for clinical translation 
Based on our findings, we consider that mC vector DNA technology can offer a new solution 
to a key translational challenge confronting therapeutic gene transfer, with significant 
implications for safe and effective genetic engineering of neural transplant cells. Our reported 
level of gene transfer is likely to be sufficient for achieving therapeutic outcomes. For 
example, a previous study reported that transplantation of vascular endothelial growth factor 
(VEGF) secreting NSCs (20-30% transfection) promoted angiogenesis following 
transplantation in the rodent brain [54].  
Due to their small size, mCs can enable the incorporation of larger genes such as receptors, or 
enzymes e.g. chondroitinase ABC, (insert size: 2kb, total mC size 4kb) without compromising 
transfection efficiency [55]. For transient gene expression in vivo, the coding sequence for the 
fluorescent tag of the mC system (size ca. 756 bp) could be replaced with neurotherapeutic 
growth factors sequences (whose open reading frames are typically <1.2 kb) without 
appreciable increases in the overall mC size, representing a realistic solution for safe genetic 
engineering of neural transplant populations with MNP vectors. While the aim of this study 
was to provide proof-of-concept that mC vector use is compatible with nanoparticle delivery 
systems, our functional study on the feasibility of this approach for therapeutic gene delivery 
indicates that DNA sequences encoding a neurotherapeutic factor (BDNF) can be inserted 
into mCs for growth factor release by engineered stem cells (see submitted manuscript, part 
II: Functional Delivery of a Neurotherapeutic Gene to Neural Stem Cells using Minicircle 
DNA and Nanoparticles: Translational advantages for Regenerative Neurology). This shows 
the high versatility of the system, which can be used for incorporation of a range of 
therapeutic sequences.  
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Of critical importance to clinical translation, is the absence of a bacterial backbone 
(containing antibiotic resistance genes and an origin of replication) in mCs.  Bacterial 
backbone sequences have been associated with inflammatory responses in vivo due to the 
presence of a high number of unmethylated CpG motifs- structures characteristic of 
prokaryotic DNA sequences, which induce the innate immune response [46]. Guidance on the 
use of medicinal products for gene transfer advise great care in the use of selection markers 
used in such products due to their significant potential to impact human therapy. This is 
especially pertinent to the presence of antibiotic resistance genes since these can restrict more 
general treatment options [30,46,56,57]. Indeed, medical and clinical regulatory bodies advise 
limiting the use of antibiotic resistance genes for therapy where feasible [58]. Further, less 
mC DNA (<100 ng per well) is required to obtain similar transfection levels as the parental 
plasmid (~250 ng per well i.e. for ca 0.9 X 10
5 
cells), so for large scale production of vectors 
encoding therapeutic genes, this could imply considerable cost and time benefits for cell 
therapies.  
 
Finally, upscaling of MNPs and mCs for clinical applications appears feasible as MNPs have 
long been used clinically as contrast agents with several methods currently being employed 
for large scale manufacture [46,59–61]. It should be noted that given their clinical utility, a 
novel method involving affinity-based chromatography has been developed for obtaining 
highly purified mC DNA for gene therapy and vaccination, enabling safe production at an 
industrial scale [33,62,63]. Together, these factors highlight the critical advantages offered by 
mC DNA vector technology in conjunction with magnetofection, for clinical translational 
applications involving genetically engineered neural transplant cells (summarized in Fig. 6).  
Moreover, mCs are likely to enhance the utility of a wide range of advanced funtional non-
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viral gene delivery materials, broadening the scope for safe and efficient genetic engineering 
of several different cell types for therapeutic applications. 
 
4. Conclusion 
As far as we are aware, this is the first reported proof of the fusion of nanovector and mC 
DNA technologies, for genetic engineering of any cell type of primary origin. We show for 
the first time that such an approach is entirely feasible for the genetic modification of NSC 
transplant populations, and that mCs can enhance the functional efficacy of transfection grade 
nanoparticles. It has become increasingly clear in recent years that it is essential to employ 
DNA vectors of the minimum size possible, to achieve maximal gene delivery when using 
nanoparticle based systems to genetically engineer neural cells. We prove here that such DNA 
size restrictions on nanoparticle based gene transfer can be overcome by deploying mC 
vectors, whose small size compared with conventional plasmids enables enhanced 
transfection outcomes to be achieved. Additionally, due to their unique structure, mCs offer a 
host of advantages for clinical translation, such as reduced immune responses, sustained gene 
expression and versatility for incorporation of a range of therapeutic sequences. Similarly, 
MNPs have high translational potential as already demonstrated by their utility as clinical 
contrast agents. Production of both mCs and MNP is feasible in terms of scale up for human 
therapies. Further, the methods involved in the genetic modification protocols are simple, 
cost-effective and reliable, highlighting the key utility of this genetic modification approach 
for translational applications.  
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Figure 6. Advantages of mC technology for cell based therapy. Schematic showing clinical 
translational potential of mCs.  
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Graphical Abstract 
 
Magnetic nanoparticle-mediated gene delivery to neural stem cells using minicircles (small 
DNA vectors) achieves significantly higher and sustained gene transfer compared to larger 
DNA vector counterparts.  
 
